Stempeutics Research

stempeutics is a leading regenerative medicine company in bangalore with our patented stem-cell therapy platform technology developing treatment of cardiovascular, immune-mediated and degenerative diseases. the company's flagship product, stempeucel® has received market authorization to treat critical limb ischemia – a major unmet medical need in india. it is the first innovative cell therapy based product to get marketing approval in india and globally. cipla, the indian licensee, has commenced pan-india commercialization. it has the first dcgi approved cell therapy product for knee osteoarthritis being marketed by alkem. stempeutics has a product in the phase 3 stage covering diabetic foot ulcer. further it is conducting phase 2 trial in perianal fistula due to crohn’s disease. stempeucel® has strong patent protection with 20 patents granted including us, europe and japan. stempeucel® has been classified as an advanced therapy medicinal product (atmp) and designated as an orphan drug for the treatment of cli due to buerger’s disease by the european medicines agency (ema) another portfolio developed by stempeutics is stempeucare® range of cosmetics. it is developed from the stem cell derived growth factors/cytokines combination for various cosmetic and derma applications including rejuvenation of aging skin, hair fall control & hair growth promotion, under eye dark circle reduction cream etc. first product which has gone to the market is an intensive firming skin care cosmetic product, branded as cutisera™. other products ready for marketing are trichosera™ for hair application and optisera™ for under eye application with a strong pipeline in cell and gene therapy products in some of the largest health and personal care segments like otc cosmetics (skin and hair care), osteoarthritis, diabetes, cli and paf stempeutics is poised to transform the cell & gene therapy space with its india first, global next approach.

查找电子邮件地址

使用 tomba.io 快速尝试一下。 tomba.io.

从列表中查找电子邮件地址从 Google 开始